Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vein access device effective in early study:

This article was originally published in Clinica

Executive Summary

An implantable device which provides access to the veins of haemodialysis patients has worked well in a preliminary study of patients at the Austin Diagnostic Center in Texas. The LifeSite device, a stainless steel and titanium alloy valve implanted just under the skin, was developed by Topsfield, Massachusetts-based VascA. According to the results of the study, it allowed increased blood flow and was free from thrombosis in all ten patients. The device, which is already sold in Canada and Europe, is designed as an alternative to fistulas, synthetic grafts and dialysis catheters.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel